Stocks
JNJ Reshapes MedTech Business with ACUVUE OASYS MAX Approval and Laminar Transfer
Johnson & Johnson (NYSE:JNJ) is making significant changes to its medical-device business, reflecting shifting demand and technological advancements in healthcare.
The company has secured European regulatory clearance for ACUVUE OASYS MAX reusable contact lenses designed for digital-device users, expanding its vision-care portfolio.
Additionally, the Laminar left atrial appendage closure program has been transferred to Jaguar LAA, marking a deliberate decision to concentrate internal resources on other areas of MedTech.
The combination of these developments suggests a more selective approach to portfolio construction, prioritizing established products and newer technologies with clear commercial pathways.